Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11485432 | 0.83 | KMT2A (0.51) | KMT2AKDM4EPOLBMAPK10SMN1; SMN2 | |
| SCHEMBL7508269 | 0.80 | EDNRA (0.35) | PTK2KMT2AACLYPTGS2MAPK10 | |
| SCHEMBL3585261 | 0.79 | CA2 (0.42) | PTK2KMT2AGAAKDM4EPOLB | |
| SCHEMBL7555210 | 0.77 | NPSR1 (0.58) | PTK2KMT2AKDM4EPOLBSMN1; SMN2 | |
| SCHEMBL1436752 | 0.74 | PTK2 (0.37) | PTK2KMT2AKDM4EPOLBSMN1; SMN2 | |
| SCHEMBL4704966 | 0.74 | MAPK1 (0.49) | GAAKDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL11482082 | 0.71 | EDNRB (0.37) | PTGS2GAASMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL22021504 | 0.70 | EDNRB (0.39) | PTGS2GAASMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL11481329 | 0.68 | PKM (0.40) | PTGS2GAASMN1; SMN2CA12CA1 | |
| SCHEMBL11473679 | 0.68 | EDNRB (0.37) | PTGS2GAASMN1; SMN2ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221408-A1 | COMPOSITION | EARTH CORPORATION (JP) | 2025-07-10 | — | — | US | disclosed |
| CN-119114152-A | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2024-12-13 | — | — | CN | disclosed |
| EP-4473837-A1 | COMPOSITION | Earth Corporation (JP) | 2024-12-11 | — | — | EP | disclosed |
| CN-118695780-A | Composition and method for producing the same | 阿斯制药株式会社 | 2024-09-24 | — | — | CN | disclosed |
| CN-110769931-B | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2024-09-17 | — | — | CN | disclosed |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | ACENET INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-117281115-A | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | 株式会社ACENET | 2023-12-26 | — | — | CN | disclosed |
| WO-2023190598-A1 | COMPOSITION | アース製薬株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230263710-A1 | ORAL CARE AGENT | OSAKA UNIVERSITY (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4230042-A1 | ANTIPATHOGENIC DRUG, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN PROCESSING DEVICE, METHOD FOR PRODUCING ANTIPATHOGENIC DRUG, ANTIBACTERIAL METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN PROCESSING METHOD | Acenet Inc. (JP) | 2023-08-23 | — | — | EP | disclosed |
| EP-0527801-B1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANHYDRASE INHIBITORS | ALCON LAB INC (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6362231-B1 | MODULATOR OF PARATHYROID HORMONE; OSTEOPOROSIS | NPS PHARMACEUTICALS, INC. | 2002-03-26 | — | — | US | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0933354-A1 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-08-04 | — | — | EP | disclosed |
| US-5240923-A | Treating glaucoma | ALCON LABORATORIES, INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0527801-A4 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0527801-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| US-5153192-A | For controlling intraocular pressure | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1991015486-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263710-A1 | ORAL CARE AGENT | TAS2R39, TAS2R40, TAS2R45 | PTK2 2478/4885KMT2A 476/4885ACLY 2566/4885 |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | EIF2AK2, HAO2, ZC3HAV1 | PTK2 3276/4885KMT2A 2886/4885ACLY 2615/4885 |
| US-20250221408-A1 | COMPOSITION | GGPS1, PGGT1B, HBG2 | PTK2 1524/4885KMT2A 4792/4885ACLY 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.